Genomic Health, Inc.

Nsabp Foundation, Inc.

Nsabp Foundations, Inc.

Wayne Cowens

Joffre B Baker

Soonmyung Paik

James Hackett

Drew Watson

Kim Clark

Audrey Goddard

Michael C Kiefer

Steven Shak

Tara Maddala

Frederick L Baehner

Michael R Crager

Maureen T Cronin

Steve Shak

Dejan Knezevic

Kim Langone

Mark Lee

Diana Cherbavaz

Robert J Pelham

Carl L Millward

Francois Collin

Kim Clark-Langane

Robert Pelham

The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.

Method to use gene expression to determine likelihood of clinical outcome of renal cancer

The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.

Method for using gene expression to determine prognosis of prostate cancer

The present disclosure provides methods for assessing a patient's cancer risk and/or recurrence risk, which methods comprise assaying, in a biological sample obtained from the gastrointestinal (GI) tract of the patient, an expression level of a risk gene. The present disclosure also provides methods involving a cancer risk/recurrence risk sequence, i.e. the V600E mutation of the BRAF gene, which is useful for assessing cancer risk and/or recurrence risk in a patient.

Methods of predicting cancer risk using gene expression in premalignant tissue

The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.

Gene expression markers for prediction of patient response to chemotherapy

A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene expression markers for colorectal cancer prognosis

Growing community of inventors

Tiburon, CA, United States of America

Wayne Cowens